



IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Original) Pharmaceutical or diagnostic composition comprising one or more active substances wherein the one or more active substance is/are selected from a group consisting of:
  - (a) active substances with a structure according to formula I-1 to I-9




Formula I-1




Formula I-2




Formula I-3




Formula I-4




Formula I-5




Formula I-6



Formula I-7




Formula I-8




Formula I-9

wherein X in formula I-2 and I-3 is H, OH, NH<sub>2</sub> or a halogen atom and X<sub>1</sub> and X<sub>2</sub> in formula I-4 are any heteroatom;

- (b) active substances with a structure according to formula II-1 or II-2




Formula II-1



Formula II-2


- (c) active substances with a structure according to formula III-1 to III-6




Formula III-1




Formula III-2



Formula III-3



Formula III-4




Formula III-5




Formula III-6

wherein X in formula III-1 and X<sub>1</sub> and X<sub>2</sub> in formula III-5 are H, OH, NH<sub>2</sub> or a halogen atom;


(d) active substances with a structure according to formula IV-1 to IV-6




Formula IV-1




Formula IV-2




Formula IV-3



Formula IV-4




Formula IV-5




Formula IV-6

X<sub>1</sub> and X<sub>2</sub> in formula IV-6 are selected from H, F, I, Br or Cl, OH or OA, SH or SA, NH<sub>2</sub>, NHA<sub>1</sub> or NA<sub>1</sub>A<sub>2</sub> or A and wherein A and/or A<sub>1</sub> and A<sub>2</sub> is/are a branched, straight-chain or cyclic alkyl or heteroalkyl group with up to 7 carbon atoms;


(e) active substances with a structure according to formula V-1 to V-4




Formula V-1



Formula V-2




Formula V-3




Formula V-4

- (f) active substances with a structure according to formula VI-1 or VI-2



Formula VI-1




Formula VI-2


wherein R<sub>1</sub> to R<sub>9</sub> and S<sub>1</sub> to S<sub>3</sub> are selected from

- (i) H, OH, NH<sub>2</sub> or a halogen atom;
  - (ii) single- or multi-branched or straight-chain alkyl or heteroalkyl groups with one or two rings and up to 10 carbon atoms;
  - (iii) cyclic alkyl or heteroalkyl groups with 1 or 2 rings or aryl or heteroaryl groups with up to 10 carbon atoms each.
2. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein the halogen atoms are selected from the group consisting of I, Cl, Br and F.
  3. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 heteroatoms each.
  4. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 3, wherein the heteroatoms are selected from a group consisting of N, O, and S.
  5. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein the alkyl, heteroalkyl, aryl or heteroaryl groups comprise 1, 2, 3 or 4 substituents each.


6. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 5, wherein the substituents are selected from a group consisting of Cl, F, Br and I.
7. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>3</sub> and R<sub>4</sub>, R<sub>4</sub> and R<sub>5</sub>, R<sub>5</sub> and R<sub>6</sub>, R<sub>6</sub> and R<sub>7</sub>, R<sub>7</sub> and R<sub>8</sub> and/or R<sub>8</sub> and R<sub>9</sub> are bridged via further atoms.
8. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula 1-5 or 1-7 is selected from:



Anthraquinone




1,8-Dihydroxy-anthraquinone (Danthron)




1,8-Dihydroxy-10H-anthracene-9-one

(Dithranol/ Anthralin)




1,8-Dihydroxy-3-methyl-10H-anthracene-9-one


(Chrysarobin)



1,2,5,8-Tetrahydroxy-anthraquinone




4-[2-(1-Amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-sulfonyl)-ethyl]-N-propyl-benzensulfonamide; and




2-Amino-benzoic acid-6-(1-amino-4-hydroxy-9,10-dioxo-9,10-dihydro-anthracene-2-yloxy)-hexyl-ester;


9. (Original) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-1 is selected from:




(1-Methyl-1*H*-perimidine-2-yl)-methanol




2-(1H-Imidazole-4-yl)-1H-perimidine




1-Ethyl-1H-perimidine




1H,3H-Perimidine-2-thione




2-Pyridine-3-yl-1H-perimidine



1,2-Dimethyl-1*H*-perimidine




4-(1*H*-Perimidine-2-yl)-benzonitrile




2-*p*-Tolyl-1*H*-perimidine






3-(1H-Perimidine-2-yl)-phenylamine; and



2-Pyridin-4-yl-2,3-dihydro-1H-perimidine.


10. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula I-2 is




8-Fluoro-1,2-dimethyl-4,5-dihydro-pyrrolo[3,2,1-ij]quinoline-6-one.

11. (Previously Presented) The pharmaceutical or diagnostic composition according to


claim 1, wherein the active substance with a structure according to formula I-4 has the following formula:




12. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 11, wherein the active substance is selected from




Phenoxazine-3-one




1,9-Dimethyl-phenoxazine-3-one




7-Amino-1,9-dimethyl-phenoxazine-3-one




7-Hydroxy-1,9-Dimethyl-phenoxazine-3-one




7-Amino-8-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one  
(alpha-amino-orcein)




8-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one  
(alpha-hydroxy-orcein)




7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one  
(beta-amino-orcein)




7-Amino-2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-1,9-dimethyl-phenoxazine-3-one  
(gamma-amino-orcein)




2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one  
(beta-hydroxy-orcein)



2,8-bis-(2,4-dihydroxy-6-methyl-phenyl)-7-hydroxy-1,9-dimethyl-phenoxazine-3-one  
(gamma-hydroxy-orcein)




beta-amino-orceimine; and




gamma-amino-orceimine.


13. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein the active substance with a structure according to formula II-2 is selected from:




*N*-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(2-dimethylaminoethyl)-formamide




*N*-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-*N*-(2-dimethylaminoethyl)-acetamide




7-Oxo-2-(2-piperidin-1-yl-ethylamino)-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile




N-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinolin-2-yl)-N-(3-dimethylamino-propyl)-formamide




*N*-(8-Cyano-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinolin-2-yl)-acetamide



2-(3-Dimethylamino-propylamino)-7-oxo-6,7-dihydro-thiazolo[4,5-*f*]quinoline-8-carbonitrile




2-[(2-Diethylamino-ethyl)-ethyl-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile




2-Amino-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile





2-[4-(3-Hydroxy-propyl)-piperazine-1-yl]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile; and



2-[Benzyl-(2-dimethylamino-ethyl)-amino]-7-oxo-6,7-dihydro-thiazolo[4,5-f]quinoline-8-carbonitrile.

14. (Previously Presented) The diagnostic composition according to claim 1, wherein the active substance or at least one of the active substances is labeled.
15. (Cancel)
16. (Previously Presented) The pharmaceutical or diagnostic composition according to claim 1, wherein the pharmaceutical or diagnostic composition furthermore comprises one or more pharmaceutically acceptable carriers, diluents or excipients.

17. (Previously Presented) A method for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases comprising administering a pharmaceutical or a diagnostic composition according to claim 1 to a subject.
18. (Previously Presented) The method according to claim 17, wherein the subject is a human being.
19. (Previously Presented) The method according to claim 17, wherein the neurodegenerative disorder is selected from a group consisting of Alzheimer's disease, Parkinson's syndrome and polyglutamine diseases.
20. (Previously Presented) The method according to claim 19, wherein the Parkinson's syndrome encompasses idiopathic Parkinson's disease as well as atypical Parkinson's syndromes associated with protein aggregation; and the polyglutamine diseases encompass Huntington's chorea, spinocerebellar ataxias of types 1, 2, 3, 6, 7 and 17, dentatorubral pallidoluysian atrophy as well as spinobulbar muscular atrophy (Kennedy syndrome).
21. (Previously Presented) The method according to claim 17, wherein the amyloid disease is selected from: Hereditary and non-hereditary prion diseases (kuru, fatal familial insomnia, Gerstmann-Straussler-Scheinker syndrome, Creutzfeld-Jacob disease, new variant of Creutzfeld-Jacob disease), dementia with Lewy bodies, primary systemic amyloidosis, secondary systemic amyloidosis with deposits of serum amyloid A, senile systemic amyloidosis, familial amyloid polyneuropathy types I and III, familial nonneuropathic amyloidosis, familial British dementia, hereditary cerebral amyloid angiopathy, hemodialysis-associated amyloidosis, familial amyloidosis-Finnish type, diabetes mellitus type II, hereditary renal amyloidosis, injection amyloidosis with deposits of insulin, medullary carcinoma of the thyroid with deposits of calcitonin, atrial amyloidosis with deposits of ANF, and inclusion body myositis.

22. (Previously Presented) The diagnostic composition according to claim 14, wherein the labeled active substance is radioactive-labeled.